June 19, 2008
Oncolin Therapeutics Announces Its Cancer Technology Will Be Presented at the 20th EORTC-NCI-AACR Symposium
Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) will be presenting its lead cancer technology at this prestigious symposium in Geneva Switzerland in October 2008. Targeted initially for brain tumors, this technology is a major breakthrough in inhibiting glycolysis, a process many tumor cells, but not normal cells, require for growth and survival. Inhibition of glycolysis "starves" tumors by blocking their ability to provide the energy needed for survival. The founding scientists have designed a drug that passes through the Blood Brain Barrier (BBB), a protective tissue which prevents most other drugs from entering the brain, where this drug is then retained in brain tumor cells selectively blocking the tumors metabolic machinery. This technology is also applicable to other cancers that are depend on glycolysis for survival such as breast and pancreatic cancers. This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson Cancer Center, the # 1 cancer treatment center in the United State according to U.S. News and World Report.
This symposium, hosted by EORTC, NCI and AACR, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. Understanding the pathways and mechanisms which cause cancer and regulate the biological behavior of tumor cells has lead to the development of numerous new agents and innovative targets for clinical trials. This conference has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development. It will bring together delegates from all over the world igniting a huge exchange of information and promoting and developing global partnerships in translational research. The conference has been developed to ensure the maximum amount of interaction and discussion
The National Cancer Institute (NCI), founded in 1971, is the principal government agency in the United States charged with coordinating the national effort against cancer. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.
The European Organization for Research and Treatment of Cancer (EORTC), is an international non-profit research organization created in 1962. The mission of the EORTC is to conduct, develop, coordinate and stimulate translational and clinical research in Europe, and to improve the management of cancer and related problems by increasing the survival and quality of life for patients.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Reports on Form 10-QSB and Annual Report on Form 10-KSB and other reports, which are on file with the Securities and Exchange Commission. Oncolin undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.